U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    +0.25 (+0.31%)
     
  • Gold

    1,668.30
    -3.70 (-0.22%)
     
  • Silver

    19.01
    -0.02 (-0.13%)
     
  • EUR/USD

    0.9800
    -0.0019 (-0.1960%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1173
    +0.0049 (+0.4424%)
     
  • USD/JPY

    144.6980
    +0.2550 (+0.1765%)
     
  • BTC-USD

    19,240.72
    -19.53 (-0.10%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Teknova to Participate in Upcoming Investor Conference

·2 min read
Alpha Teknova, Inc.
Alpha Teknova, Inc.

HOLLISTER, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference.

Morgan Stanley 20th Annual Global Healthcare Conference
September 12-14, 2022
New York, NY

Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, will participate in a fireside chat at 7:20 a.m. ET, on Tuesday, September 13, 2022. Gunstream and Lowell plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.

The live audio webcast for this conference may be accessed from the Investor Relations section of the Company’s website: https://ir.teknova.com/. The webcast and transcript will be available on the Company’s website for approximately 90 days after the event.

About Teknova
Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.

CONTACT: Investor Contacts Matt Lowell Chief Financial Officer matt.lowell@teknova.com +1 831-637-1100 Sara Michelmore MacDougall Advisors smichelmore@macdougall.bio +1 781-235-3060 Media Contact Jenn Henry Senior Vice President, Marketing jenn.henry@teknova.com +1 831-313-1259